MX2009004071A - Moduladores de bifenilsulfonilo y fenil-heteroarilsulfonilo del receptor de histamina h3 utiles para el tratamiento de trastornos relacionados con los mismos. - Google Patents
Moduladores de bifenilsulfonilo y fenil-heteroarilsulfonilo del receptor de histamina h3 utiles para el tratamiento de trastornos relacionados con los mismos.Info
- Publication number
- MX2009004071A MX2009004071A MX2009004071A MX2009004071A MX2009004071A MX 2009004071 A MX2009004071 A MX 2009004071A MX 2009004071 A MX2009004071 A MX 2009004071A MX 2009004071 A MX2009004071 A MX 2009004071A MX 2009004071 A MX2009004071 A MX 2009004071A
- Authority
- MX
- Mexico
- Prior art keywords
- histamine
- sulfonyl
- treatment
- disorders
- modulators
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 208000035475 disorder Diseases 0.000 title abstract 3
- 102000004384 Histamine H3 receptors Human genes 0.000 title abstract 2
- 108090000981 Histamine H3 receptors Proteins 0.000 title abstract 2
- 235000010290 biphenyl Nutrition 0.000 title 1
- 239000004305 biphenyl Substances 0.000 title 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 title 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract 2
- 206010041349 Somnolence Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- SBXDENYROQKXBE-UHFFFAOYSA-N 2-phenylbenzenesulfonamide Chemical class NS(=O)(=O)C1=CC=CC=C1C1=CC=CC=C1 SBXDENYROQKXBE-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000001573 Cataplexy Diseases 0.000 abstract 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 abstract 1
- 206010028735 Nasal congestion Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010062519 Poor quality sleep Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 208000032140 Sleepiness Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 229960001340 histamine Drugs 0.000 abstract 1
- 206010020765 hypersomnia Diseases 0.000 abstract 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000003631 narcolepsy Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 201000002859 sleep apnea Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/323—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85261006P | 2006-10-17 | 2006-10-17 | |
| US93435807P | 2007-06-11 | 2007-06-11 | |
| PCT/US2007/022086 WO2008048609A1 (en) | 2006-10-17 | 2007-10-16 | Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine h3-receptor useful for the treatment of disorders related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009004071A true MX2009004071A (es) | 2009-04-28 |
Family
ID=39149258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009004071A MX2009004071A (es) | 2006-10-17 | 2007-10-16 | Moduladores de bifenilsulfonilo y fenil-heteroarilsulfonilo del receptor de histamina h3 utiles para el tratamiento de trastornos relacionados con los mismos. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20100240653A1 (enExample) |
| EP (1) | EP2074086B1 (enExample) |
| JP (1) | JP2010506918A (enExample) |
| KR (1) | KR20090069333A (enExample) |
| AR (1) | AR063226A1 (enExample) |
| AT (1) | ATE512948T1 (enExample) |
| AU (1) | AU2007313180A1 (enExample) |
| CA (1) | CA2665204A1 (enExample) |
| CL (1) | CL2007002977A1 (enExample) |
| EA (1) | EA200970386A1 (enExample) |
| IL (1) | IL197892A0 (enExample) |
| MX (1) | MX2009004071A (enExample) |
| PA (1) | PA8750901A1 (enExample) |
| PE (1) | PE20081462A1 (enExample) |
| TW (1) | TW200823204A (enExample) |
| WO (1) | WO2008048609A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4198733B2 (ja) * | 2003-07-22 | 2008-12-17 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 関連性障害の予防および処置に有用な、５−ｈｔ２ａセロトニンレセプターのモジュレーターとしてのジアリールおよびアリールへテロアリールウレア誘導体 |
| TWI415845B (zh) * | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物 |
| JP2010529130A (ja) * | 2007-06-08 | 2010-08-26 | アリーナ ファーマシューティカルズ， インコーポレイテッド | （ｒ）−１−｛２−［４’−（３−メトキシ−プロパン−１−スルホニル）−ビフェニル−４−イル］−エチル｝−２−メチル−ピロリジンの結晶形、およびその組成物ならびにそれに関連する方法 |
| US9567327B2 (en) | 2007-08-15 | 2017-02-14 | Arena Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
| US20110021538A1 (en) * | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| CN102066319A (zh) * | 2008-04-16 | 2011-05-18 | 艾尼纳制药公司 | 用于合成(r)-1-{2-[4’-(3-甲氧基丙-1-磺酰基)-联苯-4-基]-乙基}-2-甲基-吡咯烷的方法 |
| US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
| CN102264354B (zh) | 2008-10-28 | 2015-03-25 | 艾尼纳制药公司 | 用于治疗5-ht2a5-羟色胺受体相关障碍的5-ht2a5-羟色胺受体调节剂组合物 |
| GB201005511D0 (en) | 2010-03-31 | 2010-05-19 | Takeda Pharmaceutical | Compounds and their use |
| FR2974729B1 (fr) * | 2011-05-02 | 2013-04-19 | Servier Lab | Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| US9365511B2 (en) * | 2013-01-09 | 2016-06-14 | Arena Pharmaceuticals, Inc. | Biphenyl-ethyl-pyrrolidine derivatives as histamine H3 receptor modulators for the treatment of cognitive disorders |
| WO2016201373A1 (en) | 2015-06-12 | 2016-12-15 | Axovant Sciences Ltd. | Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder |
| HK1247555A1 (zh) | 2015-07-15 | 2018-09-28 | Axovant Sciences Gmbh | 用於预防和治疗与神经变性疾病相关的幻觉的作为5-ht2a血清素受体的调节剂的二芳基脲和芳基杂芳基脲衍生物 |
| WO2020092604A1 (en) * | 2018-10-30 | 2020-05-07 | Concert Pharmaceuticals, Inc. | Deuterated pitolisant |
| WO2022113008A1 (en) | 2020-11-27 | 2022-06-02 | Richter Gedeon Nyrt. | Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder |
| CN115160584B (zh) * | 2022-07-06 | 2024-03-22 | 西北工业大学 | 一种基于阳离子-π与静电作用协同构筑异质孔超分子有机框架及制备方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5217986A (en) * | 1992-03-26 | 1993-06-08 | Harbor Branch Oceanographic Institution, Inc. | Anti-allergy agent |
| US5352707A (en) * | 1992-03-26 | 1994-10-04 | Harbor Branch Oceanographic Institution, Inc. | Method for treating airway congestion |
| DE69333489T2 (de) * | 1992-09-14 | 2005-04-14 | Takeda Chemical Industries, Ltd. | Heterocyclische Verbindungen und ihre Verwendung als Angiotensin II Antagonisten |
| US5541217A (en) * | 1995-05-17 | 1996-07-30 | Ortho Pharmaceutical Corporation | 4-arylcyclopenta[c]pyrrole analgesics |
| US5869479A (en) * | 1997-08-14 | 1999-02-09 | Schering Corporation | Treatment of upper airway allergic responses |
| DE19937537A1 (de) * | 1999-08-09 | 2001-03-08 | Gruenenthal Gmbh | Substituierte 2-Dialkylaminoalkylbiphenyl-Derivate |
| US20040044029A1 (en) * | 2002-08-14 | 2004-03-04 | Dart Michael J. | Azabicyclic compounds are central nervous system active agents |
| US7244852B2 (en) * | 2003-02-27 | 2007-07-17 | Abbott Laboratories | Process for preparing 2-methylpyrrolidine and specific enantiomers thereof |
| GB0308333D0 (en) * | 2003-04-10 | 2003-05-14 | Glaxo Group Ltd | Novel compounds |
| CA2561628C (en) * | 2004-04-01 | 2012-05-08 | Eli Lilly And Company | Histamine h3 receptor agents, preparation and therapeutic uses |
| US20050245543A1 (en) * | 2004-04-30 | 2005-11-03 | Pfizer Inc | Histamine-3 receptor antagonists |
| US7145005B2 (en) * | 2004-05-12 | 2006-12-05 | Abbott Laboratories | 2-(6-{2-[(2R)-2-Methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation |
| AU2005280921B2 (en) * | 2004-09-07 | 2011-05-19 | Msd K.K. | Carbamoyl-substituted spiro derivative |
| ATE466842T1 (de) * | 2004-12-03 | 2010-05-15 | Hoffmann La Roche | 3-substituierte pyridinderivate als h3- antagonisten |
| WO2006077024A2 (en) * | 2005-01-19 | 2006-07-27 | F. Hoffmann-La Roche Ag | 5-aminoindole derivatives |
| US20060188960A1 (en) * | 2005-02-18 | 2006-08-24 | Waters Stephen M | Chimeric histamine H3 receptor |
| ATE409188T1 (de) * | 2005-06-17 | 2008-10-15 | Janssen Pharmaceutica Nv | Naphthyridinverbindungen |
| SI1948607T1 (sl) * | 2005-09-16 | 2010-07-30 | Janssen Pharmaceutica Nv | Ciklopropil amini kot modulatorji histaminskega H3 receptorja |
| CN101316840B (zh) * | 2005-11-30 | 2012-08-08 | 霍夫曼-拉罗奇有限公司 | 1,5-取代的吲哚-2-基酰胺衍生物 |
| WO2007075688A2 (en) * | 2005-12-21 | 2007-07-05 | Schering Corporation | Substituted aniline derivatives useful as histamine h3 antagonists |
| AU2007227681A1 (en) * | 2006-03-15 | 2007-09-27 | Wyeth | N-substituted-azacyclylamines as histamine-3 antagonists |
| PE20080371A1 (es) * | 2006-05-19 | 2008-04-09 | Wyeth Corp | N-benzoil-y-n-bencilpirrolidin-3-ilaminas como antagonistas de histamina-3 |
| MX339668B (es) * | 2006-05-30 | 2016-06-02 | Janssen Pharmaceutica N V * | Compuestos de piridil amida sustituidos como moduladores del receptor h3 de la histamina. |
| WO2008005338A1 (en) * | 2006-06-29 | 2008-01-10 | Arena Pharmaceuticals, Inc. | Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto |
| US7648979B2 (en) * | 2007-02-07 | 2010-01-19 | Hoffmann-La Roche Inc. | 5-amido-(1H-indol-2-yl)-piperazin-1-yl-methanone derivatives |
| US7557108B2 (en) * | 2007-02-07 | 2009-07-07 | Hoffmann-La Roche Inc. | (Indol-4-yl) or (indol-5-yl)-piperazinylmethanones |
| US7507736B2 (en) * | 2007-02-07 | 2009-03-24 | Hoffmann-La Roche Inc. | Indol-2-yl-piperazin-1-yl-methanone derivatives |
| WO2008144305A1 (en) * | 2007-05-18 | 2008-11-27 | Janssen Pharmaceutica N.V. | Diaryl-substituted tetrahydroisoquinolines as histamine h3 receptor and serotonin transporter modulators |
| US20080293771A1 (en) * | 2007-05-24 | 2008-11-27 | Wyeth | Azacyclylbenzamide derivatives as histamine-3 antagonists |
| TW200918062A (en) * | 2007-09-12 | 2009-05-01 | Wyeth Corp | Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists |
| MX2010002760A (es) * | 2007-09-12 | 2010-04-01 | Wyeth Llc | Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3. |
| US20090131417A1 (en) * | 2007-11-20 | 2009-05-21 | Letavic Michael A | Substituted pyridyl amide compounds as modulators of the histamine h3 receptor |
| US8236792B2 (en) * | 2008-05-23 | 2012-08-07 | Janssen Pharmaceutica Nv | Substituted pyrrolidine amides as modulators of the histamine H3 receptor |
| US20100130477A1 (en) * | 2008-11-25 | 2010-05-27 | Astrazeneca Ab | Spirocyclobutyl Piperidine Derivatives |
-
2007
- 2007-09-28 TW TW096136478A patent/TW200823204A/zh unknown
- 2007-10-10 AR ARP070104474A patent/AR063226A1/es not_active Application Discontinuation
- 2007-10-16 AU AU2007313180A patent/AU2007313180A1/en not_active Abandoned
- 2007-10-16 WO PCT/US2007/022086 patent/WO2008048609A1/en not_active Ceased
- 2007-10-16 JP JP2009533349A patent/JP2010506918A/ja not_active Withdrawn
- 2007-10-16 AT AT07852791T patent/ATE512948T1/de not_active IP Right Cessation
- 2007-10-16 CA CA002665204A patent/CA2665204A1/en not_active Abandoned
- 2007-10-16 EA EA200970386A patent/EA200970386A1/ru unknown
- 2007-10-16 MX MX2009004071A patent/MX2009004071A/es active IP Right Grant
- 2007-10-16 KR KR1020097009992A patent/KR20090069333A/ko not_active Withdrawn
- 2007-10-16 US US12/445,795 patent/US20100240653A1/en not_active Abandoned
- 2007-10-16 EP EP07852791A patent/EP2074086B1/en active Active
- 2007-10-16 PE PE2007001398A patent/PE20081462A1/es not_active Application Discontinuation
- 2007-10-17 CL CL200702977A patent/CL2007002977A1/es unknown
- 2007-10-17 PA PA20078750901A patent/PA8750901A1/es unknown
-
2009
- 2009-04-05 IL IL197892A patent/IL197892A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2007002977A1 (es) | 2008-06-06 |
| CA2665204A1 (en) | 2008-04-24 |
| JP2010506918A (ja) | 2010-03-04 |
| WO2008048609A1 (en) | 2008-04-24 |
| AU2007313180A1 (en) | 2008-04-24 |
| US20100240653A1 (en) | 2010-09-23 |
| TW200823204A (en) | 2008-06-01 |
| KR20090069333A (ko) | 2009-06-30 |
| PA8750901A1 (es) | 2009-03-31 |
| ATE512948T1 (de) | 2011-07-15 |
| PE20081462A1 (es) | 2008-10-18 |
| EA200970386A1 (ru) | 2009-10-30 |
| EP2074086B1 (en) | 2011-06-15 |
| IL197892A0 (en) | 2009-12-24 |
| EP2074086A1 (en) | 2009-07-01 |
| AR063226A1 (es) | 2009-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009004071A (es) | Moduladores de bifenilsulfonilo y fenil-heteroarilsulfonilo del receptor de histamina h3 utiles para el tratamiento de trastornos relacionados con los mismos. | |
| WO2008153958A3 (en) | Crystalline forms of (r)-1-{2-[4'- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto | |
| EA200901546A1 (ru) | Дизамещенные амиды для усиления глутаматергических синаптических ответов | |
| NZ595625A (en) | Substituted 2-mercaptoquinoline-3-carboxamides as kcnq2/3 modulators | |
| SG163526A1 (en) | Bicyclic amides for enhancing glutamatergic synaptic responses | |
| MX2010002890A (es) | 1, 2, 3-triacin -4-onas sustituidas en la posicion 3 y 1, 3- pirimidinonas sustituidas en la posicion 3 para mejorar las respuestas sinapticas glutamatergicas. | |
| NZ573565A (en) | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | |
| NZ617334A (en) | Cyclopropyl amine derivatives | |
| NO20083710L (no) | Dihydrotienopyrimidin for behandling av betennelsesforstyrrelser | |
| MX2011007774A (es) | Derivados de isoxazol-isoxazol e isoxazol-isotiazol. | |
| BRPI0507374A (pt) | moduladores do receptor de histamina-3 | |
| UY29882A1 (es) | Antagonistas del receptor 3 de la histamina | |
| MX2011011489A (es) | Derivados de isoxazol-piridina. | |
| EA201071083A1 (ru) | Арилсульфонилпиразолинкарбоксамидиновые производные в качестве антагонистов 5-нт | |
| NI200700084A (es) | Utilización de la agomelatina para la obtención de medicamentos destinados al tratamiento del trastorno de ansiedad generalizada | |
| MX2011011273A (es) | Derivados de isoxazol-pirazol. | |
| MX2011008336A (es) | Derivados de dihidroquinolinona. | |
| DOP2011000130A (es) | 1-(arilsulfonil)-4-(pepirazin-1-il)-1h-benzimidazol como ligando de 5-hidroxitriptamina-6 | |
| NZ614567A (en) | Novel compounds as histamine h3 receptor ligands | |
| CO6331428A2 (es) | Compuestos que comprenden un grupo ciclobutoxi | |
| PT2221298E (pt) | Derivados de fenilpirazole | |
| WO2007061741A3 (en) | Modulators of the h3 receptor useful for the treatment of disorders related thereto | |
| JP2010529130A5 (enExample) | ||
| BR112013030986A2 (pt) | análogos de hiperforina, métodos de síntese e usos dos mesmos | |
| MX363632B (es) | Derivados de pirroloquinolina como antagonistas de 5-ht6, metodo de preparacion y uso de los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HH | Correction or change in general | ||
| FG | Grant or registration |